FemSelect, a Tel Aviv, Israel-based developer of an innovative approach to pelvic floor ligament fixation, raised US$9M in Series B funding.
The round was led by New Age Ventures, and TriVentures, with participation from Robin Hood Ventures, Mid Atlantic Bio Angels, MEDA Angels, Keiretsu Forum Mid-Atlantic, RAD BioMed, Keiretsu Capital and Transpacific Venture Partners. Following its investment, New Age Ventures will join FEMSelect’s Board of Directors.
The company intends to use the funds to support the growth and market penetration of EnPlace®, primarily in the US.
Led Co-CEOs Debbie Garner and Renee Selman, FEMSelect develops EnPlace®, a minimally invasive, meshless approach to pelvic floor ligament fixation. The system is cleared by the FDA for pelvic floor ligament fixation for the management of symptomatic uterine prolapse, a complication in the lives of nearly 50% of women over the age of 50. The technology enables a minimally invasive approach in under 30 minutes and clinical studies have shown women can return to normal activities within just a few days.
FEMSelect partnered with women’s healthcare company LiNA Medical USA and has been educating physicians on the technology over the past year. Earlier this year, EnPlace® obtained a procedure code from the Centers for Medicare and Medicaid Services (CMS) enabling healthcare facilities to receive reimbursement for the procedure.
It is currently available in more than 25 states across the US.
FinSMEs
20/10/2022
Co-CEO
Debbie has 20 years of experience in commercialization leadership roles. She has launched and built the market for innovative women’s health care products with Eli Lilly and Co. and iMDsoft in numerous international markets. Debbie holds an MBA from the Wharton School of Business of the University of Pennsylvania and a BA from Harvard College.
